Federal Policy
FDA Raises Safety Concerns About Compounded GLP-1 Drugs as Alternative to Ozempic
The FDA and physicians are expressing concern about compounded versions of GLP-1 drugs like Ozempic, which patients are increasingly using as cheaper, more accessible alternatives. These compounded formulations, while easier to obtain, carry serious safety risks according to medical experts. The issue affects Medicaid beneficiaries who may turn to compounded versions due to cost or access barriers with brand-name GLP-1s. This raises questions for state Medicaid programs about coverage policies, prior authorization criteria, and quality oversight for diabetes and weight management drugs.
Why it mattersState Medicaid agencies and managed care plans must balance beneficiary access to GLP-1 therapies against safety concerns about compounded alternatives, with potential implications for pharmacy benefit design, prior authorization protocols, and member education.